Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Raily Aesthetic Medicine International Holdings Limited ( (HK:2135) ) just unveiled an update.
Raily Aesthetic Medicine International Holdings Limited has issued a profit warning, reporting a significant decline in revenue and an increase in losses for the first half of 2025. The company’s revenue fell to approximately RMB85 million, down from RMB117 million in the same period in 2024, while losses attributable to the parent company increased to around RMB8 million. The decline is attributed to intense market competition and increased expenses related to share options and research and development activities. The company advises shareholders and potential investors to exercise caution as the financial results are preliminary and subject to adjustments.
More about Raily Aesthetic Medicine International Holdings Limited
Raily Aesthetic Medicine International Holdings Limited operates in the aesthetic medicine industry, offering aesthetic medical services and aesthetic medical management consulting services. The company is also involved in the research and development of medical equipment products through its subsidiary, Suzhou Ruiquan Biosciences Co., Ltd.
Average Trading Volume: 390,074
Technical Sentiment Signal: Sell
Current Market Cap: HK$70.19M
For detailed information about 2135 stock, go to TipRanks’ Stock Analysis page.